Dr. Irenej Kianicka, DVM, PhD

Senior Director, Drug Development

Irenej is an expert toxicologist, with more than 22 years of experience in preclinical and clinical drug development, and contributor to five market approvals.

He led early development programs at Vertex, Gemin X, Chronogen and Shire. While at Vertex, he was the supporting toxicologist for preclinical and early clinical development of VX-809 (now lumacaftor – marketed) and assigned team leader for the cystic fibrosis back-up programs, including VX-661 (now tezacaftor – marketed).

Irenej is a doctor in veterinary medicine (University of Kosice, Slovakia) and also holds a PhD in physiology from Sherbrooke University.